Correlation of serum PDCD5 and Bax contents with the pathological features of tumor lesions in patients with lung cancer

Objective:To study the correlation of serum PDCD5 and Bax contents with the pathological features of tumor lesions in patients with lung cancer.Methods:Patients with lung cancer who underwent surgical treatment in West China Hospital between June 2014 and March 2017 were selected as the lung cancer group for the study, the serum specimens were collected before surgery, and the lung cancer lesion and adjacent lesion were taken after surgery;the healthy subjects who underwent physical examination in West China Hospital during the same period were selected as the control group, and the serum samples were taken during the physical examination;the contents of PDCD5 and Bax in serum as well as the contents of PDCD5 and Bax, and the expression of proliferation genes and invasion genes in the lung cancer lesion and adjacent lesion were measured.Results: PDCD5 and Bax contents in serum of lung cancer group were significantly lower than those of control group, PDCD5 and Bax contents in lung cancer lesion were significantly lower than those in adjacent lesion, and the PDCD5 and Bax contents in serum of patients with lung cancer were positively correlated with the PDCD5 and Bax contents in lung cancer lesion;C-myc, RACK1, CatL, MMP2 and N-cadherin mRNA expression in lung cancer lesion were significantly higher than those in adjacent lesion and negatively correlated with PDCD5 and Bax contents in serum whereas LAST1, PAQR3, TCF21, E-cadherin, TIMP1 and TIMP2 mRNA expression were significantly lower than those in adjacent lesion and positively correlated with PDCD5 and Bax contents in serum. Conclusion:The decrease of PDCD5 and Bax in serum of patients with lung cancer is closely related to the aggravation of cancer cell proliferation and invasion in tumor lesions.

微小RNA-127对胰腺癌细胞的抑制作用及其机制

目的探讨微小RNA（miRNA，miR）-127在体外调节胰腺癌的作用及其分子机制。方法利用实时定量反转录聚合酶链反应（RT-qPCR）方法检测各种胰腺癌细胞和胰腺癌临床样本中内源性miR-127的表达；利用慢病毒载体过表达miR-127，并将其作用于胰腺癌细胞Capan-1和PANC-1细胞中，利用细胞增殖检测方法检测细胞增殖，流式细胞仪检测细胞周期，Transwell小室方法检测细胞侵袭能力；双荧光素酶检测方法和RT-qPCR方法检测miR-127的下游靶基因，B细胞淋巴瘤/白血病-2相关基因5（BAG5）；过表达BAG5在过表达miR-127的胰腺癌Capan-1和PANC-1细胞中，随后检测其效果。结果与正常胰腺导管细胞比较，miR-127在多种胰腺癌细胞株的表达从（30.0±8.1）%～（72.0±12.3）%（P＝0.004），与周围正常胰腺组织比较，胰腺肿瘤的表达为（48.0±18.2）%（P＝0.003）；通过慢病毒感染CAPAN-1和PANC-1细胞，过表达miR-127能抑制癌症增殖（P＝0.002），细胞周期阻滞在G1期，Canpan-1细胞从（49.0±6.2）%增加到（62.0±4.3）%（P＝0.010），PANC-1细胞比例从（56.0±7.1）%增加到68±4.1%（P＝0.015）和侵袭能力的下降（P＝0.004）；胰腺癌中miR-127的下游靶基因是BAG5；过表达BAG5在Capan-1和PANC-1细胞中能逆转miR-127对癌症发展的肿瘤抑制作用（P＝0.000）。结论MiR-127可作为在胰腺癌中的肿瘤抑制因子，其功能调节的下游靶基因是BAG5。